Skip to main navigation Skip to search Skip to main content

Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term Extension.

  • Antonio Brucato
  • , Lucia Trotta
  • , Michael Arad
  • , Paul C Cremer
  • , Antonella Insalaco
  • , Marc Klutstein
  • , Martin LeWinter
  • , David Lin
  • , Sushil A Luis
  • , Yishay Wasserstrum
  • , JoAnn Clair
  • , Sheldon Wang
  • , Allan L Klein
  • , Massimo Imazio
  • , John F Paolini
  • , RHAPSODY Investigators
  • , John Petersen

Research output: Contribution to journal › Article

Abstract

BACKGROUND: Rilonacept inhibits the interleukin-1 pathway, and extended treatment in patients with recurrent pericarditis (RP) reduced recurrence risk by 98% in the phase 3 trial, RHAPSODY long-term extension (LTE). Severe acute respiratory syndrome (SARS)-CoV-2 vaccination and/or infection may trigger pericarditis recurrence, and in clinical practice, it is unknown whether to continue rilonacept during SARS-CoV-2 infection. This post-hoc analysis of the RHAPSODY LTE aimed to inform rilonacept management in RP patients vaccinated against SARS-CoV-2 or who contract COVID-19.

METHODS: Analysis was conducted from May 2020 to June 2022. The LTE portion of RHAPSODY LTE enabled up to 24 months of additional open-label rilonacept treatment beyond the pivotal study. Rilonacept efficacy data in preventing pericarditis recurrence were assessed, and concomitant SARS-CoV-2 vaccination and COVID-19 adverse event data were evaluated.

RESULTS: No pericarditis recurrences were temporally associated with vaccination. Sixteen COVID-19 cases were reported; 10 in 30 unvaccinated or partially vaccinated patients (33%) vs 6 of 44 fully vaccinated patients (14%;

CONCLUSIONS: Full vaccination effectively reduced COVID-19 events in patients treated with rilonacept. Vaccination or COVID-19 during rilonacept treatment did not increase pericarditis recurrence. Continued rilonacept treatment in patients contracting COVID-19 did not worsen disease severity, whereas rilonacept interruption increased pericarditis recurrence, supporting a recommendation for continued rilonacept treatment for RP during vaccination or COVID-19.

CLINICALTRIALSGOV IDENTIFIER: NCT03737110.

Original languageUndefined/Unknown
JournalArticles, Abstracts, and Reports
StatePublished - Jun 1 2024

Cite this